BeOne Medicines (BEIGF) EPS (Weighted Average and Diluted) (2016 - 2026)
BeOne Medicines (BEIGF) reported EPS (Weighted Average and Diluted) of $0.15 for Q1 2026, up 275.0% quarter-over-quarter from $0.04 in Q4 2025.
BeOne Medicines (BEIGF) EPS (Weighted Average and Diluted) (2016 - 2026) Analysis & Trends
BeOne Medicines (BEIGF) has 10 years of EPS (Weighted Average and Diluted) data on file, last reported at $0.15 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.15, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $0.33 (up 213.79% YoY), and the FY2025 annual result was $0.19, up 140.43% from the prior year.
- EPS (Weighted Average and Diluted) advanced to $0.15 in Q1 2026 per BEIGF's latest filing, from $0.04 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.15 in Q3 2023 and troughed at -$0.42 in Q2 2022.
- A 5-year average of -$0.14 and a median of -$0.15 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2025: EPS (Weighted Average and Diluted) sank 760.0% in 2022, then surged 188.89% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.33 in 2022, then advanced by 18.18% to -$0.27 in 2023, then surged by 59.26% to -$0.11 in 2024, then soared by 136.36% to $0.04 in 2025, then soared by 275.0% to $0.15 in 2026.
- Business Quant data shows BEIGF's EPS (Weighted Average and Diluted) at $0.15 in Q1 2026, $0.04 in Q4 2025, and $0.08 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | -0.61 |
| 10 | BeOne Medicines | - | - | 1.35 Bn | 0.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.15 |
| Dec 31, 2025 | 0.04 |
| Sep 30, 2025 | 0.08 |
| Jun 30, 2025 | 0.06 |
| Dec 31, 2024 | -0.11 |
| Sep 30, 2024 | -0.09 |
| Jun 30, 2024 | -0.09 |
| Mar 31, 2024 | -0.19 |
| Dec 31, 2023 | -0.27 |
| Sep 30, 2023 | 0.15 |
| Jun 30, 2023 | -0.28 |
| Mar 31, 2023 | -0.26 |
| Dec 31, 2022 | -0.33 |
| Sep 30, 2022 | -0.41 |
| Jun 30, 2022 | -0.42 |
| Mar 31, 2022 | -0.33 |
| Dec 31, 2021 | -0.49 |
| Sep 30, 2021 | -0.36 |
| Jun 30, 2021 | -0.40 |
| Mar 31, 2021 | 0.05 |